OBiS, a New York City based company, was founded in 2002 by Rick Beasley, former Director of Oncology Market Research for Bristol-Myers Squibb. OBiS started with the development of innovative business reporting tools in the therapeutic area of oncology that helped sales representatives better prioritize their accounts and understand the competitive market.
Later OBiS expanded into the clinical trials area recognizing the growing area of patient recruitment management. OBiS has developed a range of analytical tools to support this effort and a standardized approach toward evaluating protocols in terms of their patient recruitment potential based on the key study criteria and various benchmark data sources.
In 2016, OBiS entered into the business development space by developing forecasting models and new analytical process for assessing markets and valuation of new medicines.
In July 2020, OBiS open a subsidiary office in France to expand its analytical capabilities and better serve the European markets. OBiS is planning a further expansion in Japan early next year to build its services in the rapidly expanding Asian new medicines development market.